The Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet)

The summary for the The Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Centers for Disease Control and Prevention ERA, which is the U.S. government agency offering this grant.

The Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet): The purpose of this NOFO is to better understand the public health and clinical impacts of living with MD by conducting longitudinal, population-based surveillance and research of eligible MDs (DMD, BMD, DM, FSHD, LGMD, CMD, EDMD, OPMD, and Distal MD). The current cycle will focus on identifying eligible MD cases, conducting longitudinal follow-up and research, analyzing data, and publishing and disseminating the results. Current MD STARnet sites will collect data to estimate prevalence and survival and additional clinical data on existing MD cohorts. New MD STARnet sites will focus on identifying eligible MD cases and collecting data to estimate prevalence, survival and track key clinical indicators. Identification of cases through population-based surveillance will enable existing and new sites to conduct research on these populations. This information is expected to advance understanding of diagnosed prevalence, disease progression and survival; clinical care and interventions and their alignment with recommended care; disparities in access to care; the association of treatment with outcomes, and the impact of MD on the lives of affected individuals and their families.

Federal Grant Title:	The Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet)
Federal Agency Name:	Centers for Disease Control and Prevention ERA (HHS-CDC-HHSCDCERA)
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-DD-19-002
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.315
CFDA Descriptions:	Information not provided
Current Application Deadline:	February 13th, 2019
Original Application Deadline:	February 13th, 2019
Posted Date:	December 7th, 2018
Creation Date:	December 7th, 2018
Archive Date:	March 15th, 2019
Total Program Funding:	$16,250,000
Maximum Federal Grant Award:	$375,000
Minimum Federal Grant Award:	$0
Expected Number of Awards:	15
Cost Sharing or Matching:	No
Last Updated:	December 7th, 2018

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.) - Unrestricted (i.e., open to any type of entity below), subject to any clarification in text field entitled "Additional Information on Eligibility"
Additional Information on Eligibility: For an applicant to be considered they must be responsive to the information here. Component A – Core-Current: Applicants must document current funding under RFA DD-14-001 Surveillance and Research of Muscular Dystrophies and Neuromuscular Disorders. Component B – Core-New: Applicants must propose a study site that should be a specific geographic area with a population of at least 3 million people including a large minority population (e.g. African American, Asian, or Hispanic). Component C – Enhanced-Dissemination: Applicants must submit an application for Component A to apply for Component C. To be funded for Component C, the applicant must also be funded for Component A. Applicants should document that they have applied for Component A. Component D – Enhanced-DCC: Applicants must submit an application for Component A or B to apply for Component D. To be funded for Component D, the applicant must also be funded for Component A or B. Applicants should document that they have applied for Component A or B. Component E – Enhanced-Abstractor: Applicants must submit an application for Component A to apply for Component E. To be funded for Component E, the applicant must also be funded for Component A. Applicants should document that they have applied for Component A. If your application is incomplete or non-responsive to the special eligibility requirements listed in this section, it will not enter the review process.
Grant Announcement Contact: Marcella Law
[email protected]
Grants Policy
Similar Government Grants: • Research Approaches to Improve the Care and Outcomes of People Living with Spina Bifida; • Using Longitudinal Data to Characterize the Natural History of Fragile X Syndrome to Impro...; • Surveillance and Research of Muscular Dystrophies and Neuromuscular Disorders; • Research Approaches to Improve the Care and Outcomes of
More Grants from the Centers for Disease Control and Prevention ERA: • Collaborative research on influenza and other respiratory pathogens in South Africa; • Advancing Public Health Research in Bangladesh; • Demonstration Projects to Research and Evaluate Strategies Aligned with CDC's What Works i...; • Public Health Epidemiology, Prevention and Control of Influenza and Other Respiratory Path...; • A Bridge to Adherence: Long-Acting Antiretroviral Therapy for People with HIV Released fro...